Should FDA Warning Letter Prompt Securities Suit? Government, PhRMA Disagree
This article was originally published in The Pink Sheet Daily
Executive Summary
Supreme Court is to decide when Merck investors had sufficient information to sue for securities fraud; FDA warning letter about Vioxx risks is at issue.
You may also be interested in...
Supreme Court Lets Vioxx Securities Suit Against Merck Stand
The top U.S. court clarifies when the statute of limitations for filing suit begins to run and specifies that intent to deceive is crucial in determining if a violation occurred.
Supreme Court Lets Vioxx Securities Suit Against Merck Stand
The top U.S. court clarifies when the statute of limitations for filing suit begins to run and specifies that intent to deceive is crucial in determining if a violation occurred.
Vioxx's Long Shadow: Supreme Court Skeptical Of Merck's Argument On Timing Of Securities Suits
Case could determine how much evidence is necessary for investors to bring a securities fraud suit to start the clock running on the statute of limitations.